The fibrinolytic system contains an inactive proenzyme, plasminogen, which is converted to the active enzyme plasmin by two physiological plasminogen activators: tissue-type and urokinase-type plasminogen activators (t-PA and u-PA, respectively). Plasminogen activation mediated by t-PA is mainly involved in the dissolution of fibrin at the site of vascular injury, whereas u-PA binds to a specific cellular receptor (uPAR) and plays a role in pericellular proteolysis by activating cell-bound plasminogen. The fibrinolytic system is regulated at the level of plasminogen activators by specific inhibitors such as plasminogen activator inhibitor-1 (PAI-1), and at the level of plasmin by a 2 -antiplasmin.
I-Fibrincoated 96-well plates were prepared using 125 I-fibrinogen (ca. 2000 cpm/mg) as described previously. 7) Each well received 50-80 ml of reaction mixture containing U937 cells (5ϫ 10 6 /ml) and the indicated concentrations of human plasma or plasminogen in phosphate-buffered saline (PBS) (20 mM sodium phosphate and 150 mM NaCl, pH 7.4) containing gelatin (2.5 mg/ml). After incubation for 3 h at 37°C in the absence or presence of malformin A 1 (5.0 mM), the radioactivity released was measured in terms of the amount of degraded I-fibrin. Where indicated, vitronectin, a 2 -macroglobulin, RGD peptide, and/or fibronectin were added to the reaction mixture at the indicated concentrations. In experiments using various inhibitors, cells were pretreated with an inhibitor at the indicated concentration for 5 min at 22°C.
Purification of Malformin Cofactor from Plasma Bovine citrated plasma (61 ml) was fractionated according to the ethanol precipitation method of Cohn et al. 8) Malformin cofactor activity was present in the IV-1 fraction of the precipitate wherein ca. 6% of the total amount of plasma proteins was recovered. After dialysis, the IV-1 fraction was treated with ammonium sulfate, and precipitates formed in the 25-50% saturation fraction were subjected to ionexchange chromatography on Protein PAK G-DEAE (20ϫ100 mm; Waters, Milford, MA, U.S.A.). The column was developed with a linear gradient of NaCl (0-1.0 M) in 50 mM Tris-HCl, pH 7.4, and the tailing edge of the main protein peak was pooled. After concentration, the pooled fraction was subjected to hydrophobic interaction chromatography on Protein PAK G-Butyl (8.2ϫ75 mm; waters). Proteins were eluted with a linear negative gradient of ammonium sulfate (1.3-0 M) in 50 mM Tris-HCl, pH 7.4. The fractions expressing malformin cofactor activity were further purified on TSK G3000SW (7.5ϫ600 mm; Tosoh, Tokyo, Japan). The flow-through fraction yielded 0.16 mg of partially purified malformin cofactor.
Assay for Cellular Plasminogen Activation Cellular plasminogen activation was determined as the activity required to catalyze the cleavage of Boc-VLK-MCA, a fluorogenic substrate for plasmin. A reaction mixture containing U937 cells (5ϫ10 6 /ml), plasminogen (50 nM), and Boc-VLK-MCA (20 mM) in PBS containing 1.5 mg/ml gelatin was incubated in the absence or presence of vitronectin (30 mg/ml) or malformin A 1 (5.0 mM). After incubation for 2 h at 37°C, fluorescence (excitation, 365 nm; emission, 450 nm) was measured using a model MTP-32 fluorescence microplate reader (Corona Electric, Ibaraki, Japan).
Fluorescence Imaging For actin cytostaining, U937 cells (5ϫ10 6 /ml) were incubated in PBS containing gelatin (2.5 mg/ml) and human plasma (20% (v/v)) in the absence or presence of malformin A 1 (5.0 mM) on fibrin-coated coverslips for 2 h at 37°C. After the medium was removed, the cells were fixed with paraformaldehyde (3.7% (w/v)) for 20 min at 22°C. The cells were subsequently washed with PBS, permeabilized with Triton X-100 (0.1% (w/v)) for 5 min, and incubated with Texas Red-X phalloidin (0.25 mg/ml) for 20 min in the dark. To image cell-surface plasminogen, U937 cells (5ϫ10 6 /ml) were incubated with plasminogen-deficient plasma (20% (v/v)) in the absence or presence of malformin A 1 (5.0 mM) for 2 h at 37°C. After washing, the cells were incubated with Alexa Fluor 594-labeled plasminogen (100 nM) for 2 h at 37°C. The cells were washed, bound to poly-lysine-coated coverslips by gentle centrifugation, and fixed with paraformaldehyde for 20 min at 22°C. Fluorescence imaging was performed on a confocal laser scanning microscope TCS NT (Leica Microsystems AG, Wetzlar, Germany).
Flow Cytometry U937 cells were bound to Alexa 594-plasminogen as described above. After washing with PBS and fixing with paraformaldehyde for 20 min at 22°C, flow cytometric analysis was performed on EPICS Elite (Beckman Coulter, Fullerton, CA, U.S.A.).
Other Methods Fibrinogen and plasminogen were radioiodinated using the iodine monochloride method.
9) Plasminogen was fluorescence labeled using Alexa Fluor 594 Protein Labeling Kit (Invitrogen). The NH 2 -terminal amino acid sequence was determined after transferring the proteins to polyvinylidene difluoride membranes by using a protein sequencer model 476A (Applied Biosystems, Carlsbad, CA, U.S.A.). The binding of 125 I-plasminogen to U937 cells was determined as described previously.
7)
Statistical Analysis Data were expressed as the meanϮstandard deviation (S.D.). The significant differences were analyzed using the t-test. p values of Ͻ0.05 were considered significant.
RESULTS

Purification of Plasma Cofactor for Malformin Action
The promotion of cellular fibrinolytic activity by malformin A 1 requires blood plasma (Fig. 1B) . Our previous experiments demonstrate that 6-aminohexanoic acid, a lysine analog that inhibits plasminogen-fibrin binding, abolishes the action of malformin A 1 . 4) However, as shown in Fig. 1B , plasminogen alone did not support the action of malformin A 1 . Thus, these results suggest the presence of an additional plasma cofactor required for action of malformin. We tried to purify this cofactor from bovine plasma, which is also able to support malformin activity. The cofactor was purified using ethanol precipitation and ammonium sulfate fractionation, followed by ion-exchange, hydrophobic interaction, and gel filtration chromatographies (Figs. 1C-E). Starting with 61 ml of plasma, 0.16 mg of partially purified preparation was obtained with a 536-fold increase in specific activity (Fig. 1F ). The final preparation yielded two major protein bands at approximately 78 and 180 kDa on reduced SDSpolyacrylamide gel electrophoresis (Fig. 1G) ; the two proteins were identified as vitronectin 10) and a 2 -macroglobulin, 11) respectively, on the basis of their NH 2 -terminal amino acid sequences (Fig. 1G ).
Identification and Characterization of Vitronectin as a Plasma Cofactor
To determine which protein serves as a malformin cofactor, purified preparations of vitronectin and a 2 -macroglobulin obtained from commercial sources were assayed for their activity in promoting malformin A 1 -dependent enhancement of cellular fibrinolytic activity. As shown in Fig. 2A , vitronectin or a 2 -macroglobulin alone was ineffective. On the other hand, vitronectin supported the action of malformin A 1 in the presence of plasminogen, whereas a 2 -macroglobulin was ineffective even in the presence of plasminogen ( Fig. 2A) . While the physiological plasma concentration of vitronectin is 100-400 mg/ml, 12) the minimum concentration of vitronectin as a malformin cofactor was 10 mg/ml (Fig. 2B) . Consistent with the effect of malformin on cellular fibrinolytic activity, the activity of malformin A 1 for enhancing plasminogen activation on U937 cells was observed in the presence of vitronectin (Fig. 2C) .
Vitronectin is implicated in cell adhesion, spreading, and migration as well as extracellular matrix anchoring, immune defense, and hemostasis/fibrinolysis. 13, 14) Particular domains in vitronectin play distinct roles in each of these activities. Among these, the domain containing the RGD motif is im- Fig. 2D , the RGD peptide inhibited vitronectin-dependent malformin A 1 action. Thus, the interaction between vitronectin and cellular integrin(s) seems to be essential for the action of malformin A 1 . Like vitronectin, fibronectin has the RGD motif and can act as an adhesion molecule via interactions with the integrins. 15) However, fibronectin did not exhibit any malformin cofactor activity (Fig. 2E) .
Effects of Cell-Signaling Inhibitors The binding of vitronectin to cell-surface integrins results in intracellular signaling events. Next, we investigated the possible involvement of cell signaling in malformin action by using several inhibitors. Among the inhibitors tested, wortmannin, an inhibitor of phosphatidylinositol (PtdIns) 3-kinase, abolished the effect of malformin at high concentrations (Ͼ0.1 mM), whereas the agent was ineffective at 0.01 mM-a concentration widely used to inhibit PtdIns 3-kinase (Fig. 3A) . 16) Furthermore, LY294002 (another inhibitor of PtdIns 3-kinase) did not inhibit the malformin effects (Fig. 3B) . Thus, a wortmannin-sensitive kinase(s) other than PtdIns 3-kinase seems to be involved in malformin action. In the absence of malformin A 1 , wortmannin did not affect cellular fibrinolytic activity, even at concentrations as high as 10 mM. H-7, an inhibitor of protein kinases A, C, and G, slightly potentiated malformin activity (Fig. 3C) . K252a (an inhibitor of protein kinases A, C, and G and myosin light chain kinase), calphostin C (a specific inhibitor of protein kinase C), genistein (an inhibitor of tyrosine kinases), PD98059 (an inhibitor of mitogen-activated protein kinase kinase), and U-73122 (an inhibitor of phospholipase C) minimally affected the action of malformin A 1 (Figs. 3D-H) .
Involvement of Cytoskeletal Reorganization
Cytoskeletal changes follow the binding of vitronectin to integrins and subsequent signaling events. 17) The major components of the cytoskeleton are actin and tubulin. Malformin action was abolished by the actin polymerization inhibitor, cytochalasin B, while nocodazole, an inhibitor of tubulin polymerization, had no effect (Fig. 4A) . The cytostaining experiments demonstrate that actin fibers support the formation of cellsurface filopodia-like structures in control cells (Fig. 4B,  left) . In contrast, such protrusions disappeared in the malformin A 1 -treated cells, and the surface of these treated cells appeared smooth (Fig. 4B, right) . These results suggest that the actin cytoskeleton is reorganized because of malformin A 1 activity.
Alteration of Cell-Surface Plasminogen Localization One of the possible mechanisms that lead to the activation of fibrinolysis accompanied by cytoskeletal changes is alteration of the cell-surface localization of the fibrinolytic components. The importance of local plasminogen accumulation in the fibrinolytic process is well documented. 18) When U937 cells were treated with Alexa 594-plasminogen in plasminogen-deficient plasma, partial focal localization of labeled plasminogen was observed (Fig. 5A, upper) . In the presence of malformin A 1 , the focal localization of plasminogen was more prominent (Fig. 5A, lower) . Flow cytometric analysis revealed a slight increase (1.2-fold) in plasminogen binding in the malformin A 1 -treated cells (Fig. 5B) . Malformin A 1 did not enhance the binding of 125 I-plasminogen to U937 cells in an independent experiment (Fig. 5C ). Thus, it seems probable that alteration of the cell-surface localization of plasminogen, which leads to its local accumulation, is a key process in malformin A 1 -induced fibrinolytic activation. 
DISCUSSION
Our previous experiments suggest that malformin A 1 enhances fibrinolytic activity depending on cellular function and the existence of blood plasma. 4) This property of malformin A 1 is similar to that of plactin, another cyclic pentapeptide that enhances cellular fibrinolytic activity with the aid of a plasma cofactor. 3, 19, 20) Prothrombin and a proenzyme form of plasma hyaluronan-binding protein (factor VII-activating protease) have been identified as independent plactin cofactors in plasma. Plactin leads to cell-surface single-chain u-PA activation by promoting the activation of these zymogens. 20, 21) However, malformin action does not involve the activation of u-PA. 4) Our results clearly demonstrate that malformin A 1 utilizes a distinct mechanism to promote fibrinolytic activity with vitronectin as a plasma cofactor. It is likely that vitronectin acts through binding to cell-surface integrins since the RGD peptide, a competitor of vitronectinintegrin interaction, abolishes the vitronectin-dependent malformin action (Fig. 2D) . In addition, inhibition of cell signaling by wortmannin (Fig. 3A) and disruption of cytoskeletal organization by cytochalasin (Fig. 4A ) diminish malformin activity. Since cellular binding of vitronectin leads to a cellsignaling event and subsequent cytoskeletal reorganization, 17) the collective interpretation of these results indicate that vitronectin-mediated cytoskeletal reorganization is required for malformin action. The final consequence of vitronectin-dependent malformin action is likely to be the alteration of plasminogen localization on the cell surface (Fig. 5A ). This change may account for an increase in cell-surface plasminogen activation (Fig. 2C) . Although cytoskeletal reorganization is implicated in cellular fibrinolytic activity through changes in u-PA expression, 22, 23) the possibility that malformin increases u-PA activity is excluded.
4) The inhibition of cellular protein synthesis did not affect the activity of malformin (data not shown).
Vitronectin can stabilize PAI-1, 24) and therefore, affect the fibrinolytic system by enhancing plasminogen activator neutralization. In our experiments, vitronectin increased the fibrinolytic activity of U937 cells, but did not decrease even in the absence of malformin A 1 (Figs. 2A, B) . Thus, the stabilization of PAI-1 by vitronectin may not be significant in our system; alternatively, this antifibrinolytic effect can be overcome by a hitherto uncharacterized profibrinolytic action of vitronectin. It is unlikely that the activity of malformin is due to the modulation of PAI-1 stabilization by vitronectin since malformin action is abolished by inhibitors of vitronectin-integrin binding, cell signaling, and cytoskeletal organization. The cellular binding of vitronectin can alternatively occur via uPAR. 25) Unlike vitronectin-integrin interactions, this binding is not inhibited by the RGD peptide. 25) Thus, it is also unlikely that the activity of malformin involves vitronectin binding to uPAR.
Integrins recognize the RGD epitope in various extracellular matrix proteins. Fibronectin, an RGD-containing protein, plays a role in cell adhesion, migration, and proliferation. Fibronectin-integrin binding triggers cell signaling and cytoskeletal reorganization. 26) Although these effects are similar to those caused by vitronectin, fibronectin failed to promote malformin A 1 -dependent fibrinolytic enhancement in U937 cells (Fig. 2E . Thus, vitronectin-specific integrin signaling may be involved in malformin action. Vitronectin-integrin binding is followed by cell-signaling events. Among the signaling inhibitors tested in this study, only wortmannin was effective in suppressing malformin action (Fig. 3A) . Wortmannin is an inhibitor of PtdIns 3-kinase, while the high concentration of wortmannin (0.1-1.0 mM) can inhibit PtdIns 4-kinase that provides PtdIns 4-monophosphate and PtdIns 4,5-bisphosphate, which regulate cytoskeletal rearrangement, [27] [28] [29] and myosin lightchain kinase, which is implicated in the integrin signaling. 30) Malformin action is inhibited by wortmannin at high concentrations (1.0 mM). Malformin may modulate a cell-signaling event mediated by one of the kinases that is inhibited by higher concentrations of wortmannin.
Malformin was first identified as a fungal metabolite that induces curvature in plant roots. However, the molecular mechanism underlying its activity remains unknown. Recent reports state that malformin affects the G 2 checkpoint in the cell cycle after DNA damage. 31) Since cell cycle regulation involves signaling events, this suggests the presence of a target for malformin shared by vitronectin signaling and cell cycle regulation. It is tempting to speculate that the action of malformin on cell signaling plays a role in the induction of malformation in plant roots.
